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Abstract
Background: Hemodialysis patients have a greater risk of cardiovascular disease, their major cause of death.
Obesity is a risk factor for arteriosclerosis, cardiovascular disease, and mortality in the general population.
Conversely, an increased body mass index (BMI) is known to be associated with better survival of hemodialysis
patients. However, the influences of changes in parameters associated with obesity on arteriosclerosis in these
patients have not been evaluated. Here, we evaluated the relationship between changes in parameters associated
with obesity and brachial-ankle pulse wave velocity (baPWV), as an index of arteriosclerosis, in hemodialysis patients.
Methods: Two hundred and fifty-eight subjects were selected from patients undergoing stable hemodialysis. BMI,
abdominal circumference (AC), visceral fat area (VFA) and subcutaneous fat areas (SFA), and baPWV were assessed
at baseline and 4 years later. Ankle-brachial index and baPWV were measured on a non-dialysis day using volume-
plethysmographic apparatus. Abdominal circumference was measured at the level of umbilicus by computed
tomography (CT). Body fat distribution was determined using CT. All CT scans were performed on a non-dialysis
day with the subject in a supine position.
Results: Sixty-one patients died during the 4-year period. Abdominal circumference, BMI, VFA, and SFA were
higher, and baPWV was lower in patients who survived than in those who died. During the study period, baPWV
increased and was positively correlated with the change in visceral plus subcutaneous fat area in patients whose
initial VFA was > 100 cm2. There were negative correlations between the change in baPWV and changes in AC, and
SFA in individuals whose VFA was < 100 cm2.
Conclusions: These data suggest that patients with a large VFA should adopt strategies aimed at reducing body
weight, while patients with a small VFA should avoid undernutrition.
Keywords: Visceral fat area, Subcutaneous fat area, Brachial-ankle pulse wave velocity, Cardiovascular disease,
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Background
Patients undergoing hemodialysis (HD) have a greater
risk of arteriosclerotic complications and a poor progno-
sis due to the greater prevalence of cardiovascular (CV)
diseases. The risk factors include hypertension, diabetes
mellitus, vascular calcification, and inflammation.
Obesity has been recognized as a risk factor for arterio-
sclerosis and higher mortality and morbidity from CV
disease in the general population. In addition, a positive
relationship between visceral fat accumulation and ar-
teriosclerosis has been reported in diabetic HD patients
[1]. In contrast, an inverse association has been reported
in female HD patients [2]. It has been proposed that the
relationships between obesity-associated parameters and
arteriosclerosis are complicated by the existence of
malnutrition-inflammation-atherosclerosis (MIA) syn-
drome in these patients [3], and the influences of
changes in obesity-related parameters on arteriosclerosis
in patients undergoing long-term HD have not been
evaluated.
Brachial-ankle pulse wave velocity (baPWV), which is
an easily performed, non-invasive measurement, is a
marker of arteriosclerosis of both central elastic and per-
ipheral muscular components of the circulation [4]. In
the general population, high baPWV is an independent
predictor of mortality [5], and we have shown that
baPWV is a predictor of CV outcome in patients under-
going HD [6], indicating that baPWV is a useful index of
arteriosclerosis in HD patients.
Therefore, in this study, we aimed to determine the re-
lationship between changes in parameters associated
with obesity and baPWV in HD patients.
Methods
Patient recruitment
This study was approved by the ethics committee of
Moriguchi Keijinkai Hospital (approval no.: 3003). All
participants were enrolled after providing written in-
formed consent. The participants were outpatients
undergoing maintenance dialysis at Kadoma Keijinkai
Clinic in Kadoma City, Neyagawa Keijinkai Clinic in
Neyagawa City, or Moriguchi Keijinkai Clinic in Morigu-
chi City, Osaka, Japan. Patients were selected from those
who were undergoing regular dialysis treatment and
were hemodynamically stable during dialysis. Patients
with malignancy and amputation of both legs were ex-
cluded in this study. The enrollment period was from
January 2013 to December 2013.
Patient characteristics
At enrollment, information was collected regarding the
age, gender, BMI, duration of HD, presence of diabetes,
and use of anti-hyperlipidemic drugs. Diabetes was diag-
nosed when the patients were already under treatment
with an oral hypoglycemic agent or insulin, or met the
World Health Organization criteria [7] in the past or
present. Pre-dialysis systolic and diastolic blood pres-
sures (BPs) and pre-dialysis values of hemoglobin, high-
density lipoprotein cholesterol (HDL-c), low-density
lipoprotein cholesterol (LDL-c), triglyceride, uric acid,
creatinine, c-reactive protein (CRP), calcium, inorganic
phosphorus, intact parathyroid hormone, albumin, and
hemoglobin A1c were measured on the first dialysis day
of the week. Post-dialysis value of human atrial natri-
uretic peptide (hANP), brain natriuretic peptide (BNP),
and cardiothoracic ratio (CTR) were measured on the
first dialysis day of the week.
Ankle-brachial index and brachial-ankle pulse wave
velocity
Ankle-brachial index (ABI) and baPWV were measured
on a non-dialysis day using a volume-plethysmographic
apparatus (Omron Healthcare Co., Ltd., Kyoto, Japan),
as previously described [8]. The higher of the values for
each leg was accepted as the baPWV value. Because
baPWV cannot be estimated accurately when ABI is <
0.9, due to a reduction induced by arterial occlusion [9],
lower limbs with an ABI of < 0.9 were excluded from
the analysis of baPWV.
Computed tomography
Abdominal circumference (AC) was measured at the
level of the umbilicus by computed tomography (CT)
using Ziostation 2 software (Ziosoft, Tokyo, Japan). Body
fat distribution was determined using CT. All CT scans
were performed on a non-dialysis day with the subject in
a supine position, using an 80-slice multidetector CT
scanner (Aquilion PRIME, Canon medical systems Cor-
poration, Tochigi, Japan). Three-millimeter-thick slices
were acquired. The subcutaneous fat layer was defined
as the layer lying between the skin and abdominal
muscle that showed attenuation from − 60 to − 160 HU.
The component of the image with the same density as
the subcutaneous fat layer in the abdominal cavity was
defined as the visceral fat. The subcutaneous fat area
(SFA) and VFA were measured in a slice at the level of
the umbilicus.
The CT attenuation of adipose tissue is thought to be
approximately − 60 to − 160 HU. However, when adi-
pose tissue is edematous, this value is higher because of
the presence of water (attenuation = 0). In such cases,
accurate measurement of fat area by CT is impossible.
Therefore, we did not include patients with gross edema
in our analysis. In our study, the presence of gross
edema was defined by the area with a radiodensity of −
60 to − 160 HU being smaller than that with a radioden-
sity of − 30 to − 50 HU at the level of the umbilicus.
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Consequently, 12 patients were not included in our
analysis.
Study protocol
Patient characteristics were recorded at baseline, and the
BMI, AC, VFA, SFA, and baPWV were measured at
baseline and 4 years later. Comparison of patients’ char-
acteristics between those who survived and those who
died was done. Of the patients who survived, those with
complete data at baseline and 4 years later were analyzed
for the influences of changes in obesity-related factors
on arteriosclerosis over a 4-year period.
Statistical analysis
Data are expressed as mean ± SD. Statistical compari-
sons between patients who survived and those who
died were performed using Student’s t test or Fisher’s
exact test. Paired t tests were used to assess changes
over the 4-year period in patients who survived and
had complete data at baseline and 4 years later. Pear-
son’s correlation coefficient was used to evaluate the
relationships between the change in baPWV and
changes in other obesity-related parameters over the
period of the study. P < 0.05 was considered to repre-
sent statistical significance. All analyses were per-
formed using EZR (Saitama Medical Center, Jichi
Medical University, Saitama, Japan) [10].
Results
A total of 258 patients were enrolled in the study. Table 1
shows details of the characteristics of the study subjects.
Out of 258 patients, 61 patients died within 4 years. The
patients’ flowchart is presented in Fig. 1.
Comparison of patients’ characteristics between those
who survived and those who died is shown in Table 2.
Age, presence of diabetes, hANP, BNP, CTR, and
baPWV were significantly higher in patients who died
than in those who survived. BMI, serum creatinine,
serum albumin, AC, VFA, and SFA were significantly
lower in patients who died than in those who survived.
Of the patients who survived, 102 patients with
complete data were analyzed for the influences of
changes in obesity-related factors on arteriosclerosis
over a 4-year period. The characteristics of these 102 pa-
tients at baseline are shown in Table 3. The BMI (initial
value 22.4 ± 3.0 kg/m2, final value 22.2 ± 3.3 kg/m2), AC
(initial value 83.4 ± 8.6 cm, final value 82.6 ± 9.4 cm),
VFA (initial value 86.2 ± 54.4 cm2, final value 85.7 ±
54.0 cm2), and SFA (initial value 120.1 ± 62.7 cm2, final
value 117.9 ± 60.2 cm2) did not significantly change dur-
ing the study period. baPWV significantly increased (ini-
tial value 1913 ± 446 cm/s, final value 2029 ± 546 cm/s;
P < 0.01), while BPs did not significantly change (sBP
initial value 145 ± 22 mmHg, final value 145 ± 21
mmHg; dBP initial value 79 ± 12 mmHg, final value 77
± 13 mmHg).
Of these 102 patients, 36 had an initial VFA of ≥ 100
cm2, which meets the Japanese obesity criteria [11]. In
these patients, the change in baPWV over 4 years was
significantly positively correlated with the changes of
VFA + SFA (r = 0.33, P < 0.05) (Table 4). Sixty-six
patients had an initial VFA of < 100 cm2. In these
patients, the change in baPWV over 4 years was
significantly negatively correlated with the changes in
AC (r = − 0.333, P < 0.01), SFA (r = − 0.367, P < 0.01),
and VFA + SFA (r = − 0.297, P < 0.05) (Table 4).
Discussion
There were three main findings in this study. First,
baPWV was higher and BMI, AC, VFA, and SFA were
lower in the patients who died than in those who
Table 1 Characteristics of the study subjects
Number of patients 258
Age (years) 67.4 ± 12.1
Gender (m/f) 146/112
Body mass index (kg/m2) 22.2 ± 3.7
Dialysis history (months) 63.2 ± 55.4
Diabetes (%) 123 (47.7)
Hyperlipidemia drugs (%) 35 (13.6)
Systolic BP (mmHg) 152 ± 22
Diastolic BP (mmHg) 76 ± 14
Laboratory study
Hemoglobin (g/dl) 10.8 ± 1.0
High-density lipoprotein cholesterol (mg/dl) 46.8 ± 14.6
Low-density lipoprotein cholesterol (mg/dl) 88.7 ± 29.4
Triglyceride (mg/dl) 103.2 ± 65.5
Uric acid (mg/dl) 7.2 ± 1.3
Creatinine (mg/dl) 9.6 ± 2.5
C-reactive protein (mg/dl) 0.34 ± 0.70
Ca (mg/dl) 8.9 ± 0.5
Inorganic phosphorus (mg/dl) 5.2 ± 1.2
Intact-parathyroid hormone (pg/ml) 143.4 ± 85.0
Albumin (g/dl) 3.7 ± 0.3
Hemoglobin A1c (%) 5.34 ± 0.85
Human atrial natriuretic polypeptide (pg/ml) 69.3 ± 107.9
Brain natriuretic peptide (pg/ml) 264.5 ± 404.1
Cardiothoracic ratio (%) 52.3 ± 5.3
Brachial-ankle pulse wave velocity (cm/s) 2041 ± 654
Abdominal circumference (cm) 83.5 ± 10.3
Visceral fat area (cm2) 84.7 ± 59.2
Subcutaneous fat area (cm2) 118.2 ± 73.0
Values are expressed as mean ± SD
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survived. Second, baPWV increased over the 4-year
period of the study. Third, the change in baPWV was
positively correlated with the changes in obesity-related
parameters in patients whose initial VFA was ≥ 100 cm2
and was negatively correlated with the change in
obesity-related parameters in those whose initial VFA
was < 100 cm2. These findings suggest that increasing
obesity in individuals with a large visceral fat area and
decreasing adiposity in individuals with a low visceral fat
area are both associated with the progression of
arteriosclerosis.
Characteristics of patients who survived and those who
died
There were significant differences in some of the charac-
teristics of the patients who died and those who survived
the 4-year study period. BMI, serum albumin, and adi-
posity were significantly lower among those who died.
Thus, in this study, good nutritional status and slightly
greater fat accumulation were beneficial for HD patients,
trends which are consistent with previous reports [12,
13]. Higher AC was also beneficial in our study. The
hANP and BNP are known to be independent risk fac-
tors for CV and overall mortality in HD patients [14,
15], and in our study, they were significantly higher in
the patients who died. High baPWV is thought to be a
risk factor for CV and overall mortality [5], and in terms
of the mortality of HD patients, the same trends of high
CTR [16] and concomitant diabetes [13] were identified
in this study as in previous reports. In addition, the mor-
tality rate during 4 years was 24.6% in this study, which
is almost equivalent to that of Japanese dialysis patients
whose crude death rate is about 10%/year [17]. On the
basis of these consistent findings, the patients in our
study appear to be representative HD patients.
Time-dependent change in brachial-ankle pulse wave
velocity in hemodialysis patients
Patients undergoing HD have a greater risk of arterio-
sclerotic complications and a poor prognosis due to the
greater prevalence of CV diseases [18–20]. Most HD pa-
tients are thought to have developed arteriosclerosis by
the time they commence HD, and afterwards, arterio-
sclerosis is thought to be accelerated [21]. However, the
natural course of PWV has not been comprehensively
assessed in longitudinal studies. Avramovski et al.
showed in a comparison of 80 HD patients and 60 con-
trols that carotid-femoral PWV was higher in HD pa-
tients at baseline, but increased more in these patients
over a 36-month period [22]. In the present study, we
have shown that baPWV increased during a 4-year
period in 102 HD patients. PWV has been reported to
reflect not only arterial stiffness but also the BPs at the
time of PW measurement [23]. In this study, however,
the BPs did not show significant changes. Therefore,
high baPWV is considered to reflect progression of
Fig. 1 Patients’ flowchart
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arteriosclerosis, supporting the notion that the natural
course of arteriosclerosis is accelerated in patients
undergoing HD.
Influences of changes in obesity-related parameters on
arteriosclerosis in hemodialysis patients
Accumulation of visceral fat is a risk factor for arterio-
sclerosis. Abdominal visceral fat mass is positively asso-
ciated with carotid-femoral PWV in healthy subjects
[24]. There is also a positive relationship between ab-
dominal VFA and baPWV in diabetic patients [25] and
diabetic HD patients [1]. However, an inverse association
was found between abdominal visceral fatness and
baPWV in female HD patients [2]. Thus, it is unclear
whether the accumulation of visceral fat is a risk factor
for arteriosclerosis in HD patients. In addition,
overweight, hypertension, and hyperlipidemia, which are
cardiovascular risk factors in the general population,
have been reported to correlate with lower mortality in
HD patients, a phenomenon that is known as “reverse
epidemiology,” the “risk factor paradox,” and the “obesity
paradox.”
In this study, increasing obesity in patients with high
VFA and decreasing adiposity in patients with low VFA
were associated with the development of arteriosclerosis.
There are likely to be two different etiologies that may
explain this phenomenon. One is the metabolic syn-
drome, and the other is the MIA syndrome. Obesity and
insulin resistance are believed to be at the core of most
cases of metabolic syndrome, and patients may have a
greater risk of diseases such as cardiovascular disease
[26]. The MIA syndrome features a strong relationship
Table 2 Comparison of characteristics of the patients who survived and those who died
Survival Death
Number of patients 187 61
Age (years) 65.7 ± 12.1 73.7 ± 9.8 P < 0.01
Gender (m/f) 102/85 35/26 NS
Body mass index (kg/m2) 22.5 ± 3.6 20.9 ± 3.5 P < 0.01
Dialysis history (months) 64.9 ± 55.7 61.0 ± 57.2 NS
Diabetes (%) 80 (43) 41 (67) P < 0.01
Hyperlipidemia drugs (%) 22 (12) 12 (20) NS
Systolic BP (mmHg) 152 ± 20 150 ± 26 NS
Diastolic BP (mmHg) 77 ± 14 73 ± 14 NS
Laboratory study
Hemoglobin (g/dl) 10.8 ± 0.9 10.9 ± 1.0 NS
High-density lipoprotein cholesterol (mg/dl) 47.9 ± 15.3 43.9 ± 12.7 NS
Low-density lipoprotein cholesterol (mg/dl) 87.5 ± 29.2 91.6 ± 30.2 NS
Triglyceride (mg/dl) 100 ± 58 114 ± 87 NS
Uric acid (mg/dl) 7.2 ± 1.4 7.0 ± 1.3 NS
Creatinine (mg/dl) 9.9 ± 2.6 8.6 ± 2.1 P < 0.01
C-reactive protein (mg/dl) 0.3 ± 0.7 0.5 ± 0.8 NS
Ca (mg/dl) 8.9 ± 0.5 8.9 ± 0.5 NS
Inorganic phosphorus (mg/dl) 5.2 ± 1.1 5.1 ± 1.0 NS
Intact-parathyroid hormone (pg/ml) 139 ± 80 151 ± 96 NS
Albumin (g/dl) 3.7 ± 0.3 3.5 ± 0.4 P < 0.01
Hemoglobin A1c (%) 5.3 ± 0.8 5.5 ± 1.0 NS
Human atrial natriuretic polypeptide (pg/ml) 60 ± 55 103 ± 197 P < 0.01
Brain natriuretic peptide (pg/ml) 216 ± 241 429 ± 693 P < 0.01
Cardiothoracic ratio (%) 51.7 ± 4.7 54.8 ± 6.3 P < 0.01
Brachial-ankle pulse wave velocity (cm/s) 1971 ± 540 2317 ± 894 P < 0.01
Abdominal circumference (cm) 84.4 ± 10.3 80.6 ± 10.1 P < 0.05
Visceral fat area (cm2) 89.8 ± 62.1 69.2 ± 49.7 P < 0.05
Subcutaneous fat area (cm2) 124.8 ± 71.3 97.6 ± 76.3 P < 0.05
Values are expressed as mean ± SD
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between malnutrition, inflammation, and atherosclerosis
in dialysis patients, associated with a high mortality rate
[3]. In this study, increasing obesity in patients with high
VFA was associated with the development of arterio-
sclerosis, likely due to metabolic syndrome, whereas de-
creasing adiposity in patients with low VFA was also
associated with the development of arteriosclerosis, but
this was likely due to the MIA syndrome. Thus, the
present study suggests that patients with a large visceral
fat area are advised to adopt strategies aimed at reducing
body weight, while patients with a small visceral fat area
should avoid undernutrition. Patients failing to follow
Table 3 Characteristics of the surviving patients who were included in the final analysis
Baseline Study end
Number of patients 102
Age (years) 65.4 ± 12.1 –
Gender (m/f) 54/48 –
Body mass index (kg/m2) 22.4 ± 3.0 22.2 ± 3.3
Dialysis history (months) 66.4 ± 57.6 –
Diabetes (%) 42 (41) –
Hyperlipidemia drugs (%) 10 (9.8) –
Systolic BP (mmHg) 145 ± 22 145 ± 21
Diastolic BP (mmHg) 79 ± 12 77 ± 13
Laboratory study
Hemoglobin (g/dl) 10.9 ± 0.9 –
High-density lipoprotein cholesterol (mg/dl) 47.9 ± 16.0 –
Low-density lipoprotein cholesterol (mg/dl) 86.1 ± 28.4 –
Triglyceride (mg/dl) 96.9 ± 54.0 –
Uric acid (mg/dl) 7.3 ± 1.2 –
Creatinine (mg/dl) 10.2 ± 2.6 –
C-reactive protein (mg/dl) 0.25 ± 0.70 –
Ca (mg/dl) 8.9 ± 0.6 –
Inorganic phosphorus (mg/dl) 5.1 ± 1.1 –
Intact parathyroid hormone (pg/ml) 129.6 ± 82.8 –
Albumin (g/dl) 3.7 ± 0.3 –
Hemoglobin A1c (%) 5.23 ± 0.75 –
Human atrial natriuretic polypeptide (pg/ml) 62.7 ± 63.5 –
Brain natriuretic peptide (pg/ml) 214.3 ± 263.5 –
Cardiothoracic ratio (%) 51.7 ± 4.8 –
Brachial-ankle pulse wave velocity (cm/s) 1913 ± 446 2029 ± 546
Abdominal circumference (cm) 83.4 ± 8.6 82.6 ± 9.4
Visceral fat area (cm2) 86.2 ± 54.4 85.7 ± 54.0
Subcutaneous fat area (cm2) 120.1 ± 62.7 117.9 ± 60.2
Values are expressed as mean ± SD
Table 4 Correlation with ΔbaPWV
ΔBMI ΔAC ΔVFA ΔSFA ΔVFA + SFA
All patients (n = 102) r = − 0.0532
p = 0.595




r = − 0.0939
p = 0.348
r = − 0.0229
p = 0.819










Patients with VFA < 100 cm2 (n = 66) r = − 0.237
p = 0.0549
r = − 0.333
p = 0.00626
r = − 0.177
p = 0.155
r = − 0.367
p = 0.00245
r = − 0.297
p = 0.0156
baPWV brachial-ankle pulse wave velocity, BMI body mass index, AC abdominal circumference, VFA visceral fat area, SFA subcutaneous fat area
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these instructions may have a high risk of arterioscler-
osis and should be followed carefully.
Limitations
Several limitations of the present study should be men-
tioned. First, a small number of patients were studied.
Second, because many patients were lost to follow-up
because they died or because of missing data, no more
than 40% of enrolled patients were analyzed for the in-
fluences of changes in obesity-related factors on arterio-
sclerosis. Third, we did not compare changes in baPWV
with general population. Fourth, we do not have data in-
vestigating if reducing VFA and SFA can improve the
prognosis of patients with large VFA. Moreover, associa-
tions between obesity-related parameters, such as adipo-
cytokines and arteriosclerosis, were not evaluated in this
study. Larger-scale longitudinal studies investigating the
mechanism by which a change in VFA affects the pro-
gression of arteriosclerosis in HD patients are required.
Conclusions
In this study, we found that over the 4-year period,
baPWV increased, and the change in baPWV was higher
in patients who initially had a high VFA and gained add-
itional adipose tissue mass, and was also higher in pa-
tients who initially had a low VFA and lost adipose
tissue mass. Physicians should advise patients with a
large visceral fat area not to gain weight, and conversely,
those with small visceral fat area not to risk
undernutrition.
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